Alipay’s Xiang Hu Bao Online Mutual Aid Platform Attracts 100 Million Participants in One Year
27.11.2019 09:30:00 EET | Business Wire | Press release
Xiang Hu Bao, an online mutual aid platform introduced by Alipay, has attracted over 100 million participants since it was launched just over a year ago, helping health protection in China become more inclusive by making it more accessible especially for the lower income and those living in rural areas.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191126005952/en/
100 million participants signed up for Xiang Hu Bao in one year. (Graphic: Business Wire)
As of November 22, 2019, more than 10,000 people have received financial aid for their medical needs through Xiang Hu Bao, contributed by other participants in the platform. More than two thirds of Xiang Hu Bao participants earn below RMB 100,000 (US$ 14,000) per year, while a third of them come from rural China.
Xiang Hu Bao, which literally means “mutual protection”, was launched in October 2018 and provides its participants with a basic health plan against 100 types of critical illness, including thyroid cancer, breast cancer, lung cancer, critical brain injury and acute myocardial infarction. All participants share the risk of becoming critically ill and bear the related medical expenses as a collective. While Xiang Hu Bao is not a health insurance product, it complements premium health insurance offerings in the market that have wider range and depth of coverage.
“Xiang Hu Bao was designed with inclusiveness in mind,” said Ming Yin, Vice President of Ant Financial. “We hope Xiang Hu Bao can support participants to help one another by providing a trustworthy platform in addition to the medical care protection provided by China’s social security and premium health insurance companies.”
Unlike traditional online mutual aid platforms in China, Xiang Hu Bao is more inclusive because it requires no upfront payment or admission fees. It is available to participants between 30 days and 59 years of age who meet basic health and risk criteria. When a participant makes a claim, supporting evidence must be submitted via the Alipay app and then it goes through a review and approval process. Traditionally, online mutual aid platforms in China lacked cost-effective capabilities to reduce the risk of fraud, impacting their reputation and therefore prevented them from scaling up to help those people truly in need.
On the Xiang Hu Bao platform, the entire evidence submission process is powered by Alipay’s proprietary consortium blockchain technology, which ensures the process is tamper-proof. Once claims are approved, the participant will receive a one-time payout of up to RMB 300,000 (~US$43,000), the cost of which is shared equally by the other participants. Disputed claims are escalated to an online review board that consists of qualified volunteer participants.
According to Xiang Hu Bao, around six out of ten of its participants come from third and lower tier cities, counties and rural areas. A recent survey conducted by Health Economics and Medical Security Research Center, Nankai University1 examined the annual income of Xiang Hu Bao participants and discovered that two thirds of them earn less than RMB 100,000 (~US$ 14,000). Not surprisingly, around 86% of participants cannot afford medical expenses exceeding RMB 300,000 (~US$ 43,000). Also, the survey shows that 10 percent of Xiang Hu Bao’s participants had no other health plans other than Xiang Hu Bao.
“The majority of Xiang Hu Bao’s participants are from middle or low-income communities who are at great risk of falling into poverty if they become critically ill,” said Zhu Minglai, director at the Health Economics and Medical Security Research Center, Nankai University, adding that Xiang Hu Bao has enabled low-income communities to receive basic health protection at an affordable cost and supplements other health plans provided by the public and private sectors in China.
In addition to creating value for its participants, Xiang Hu Bao also helps cultivate a greater understanding of the benefits for obtaining protection against illnesses. According to an FT Confidential Research survey,2 one in three of Xiang Hu Bao’s participants intend to buy a critical illness insurance product over the next six months, while for those who do not participate in the platform, the intention of purchasing is only 22 percent. Furthermore, sales of health policies offered by partner insurance companies on the Ant Insurance Platform have increased by over 60% as of June 2019, in comparison to October 2018 when Xiang Hu Bao was launched.
About Alipay
Operated by Ant Financial Services Group, Alipay is the world’s leading payment and lifestyle platform. Launched in 2004, Alipay serves over 1.2 billion users with its local e-wallets partners as of June 2019. Over the years, Alipay has evolved from a digital wallet to a lifestyle enabler. Users can hail a taxi, book a hotel, buy movie tickets, pay utility bills, make appointments with doctors, or purchase wealth management products directly from within the app. In addition to online payments, Alipay is expanding to in-store offline payments both inside and outside of China. Alipay’s in-store payment service covers over 50 markets across the world, and tax reimbursement via Alipay is supported in 35 markets. Alipay currently supports 27 currencies, and works with over 250 overseas financial institutions and payment solution providers to enable cross-border payments for Chinese travelling overseas and overseas customers who purchase products from Chinese e-commerce sites.
1 Source: https://mp.weixin.qq.com/s/HjRYY9jsbpe2LWhabI0ijw (in Chinese)
2 Source: https://www.ft.com/content/3bbf683e-a325-11e9-974c-ad1c6ab5efd1
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191126005952/en/
Contact information
Alipay / Xiang Hu Bao
Le SHEN
E: shenle.sl@antfin.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 11:15:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 20:42:00 EEST | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 17:19:00 EEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 17:15:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 16:00:00 EEST | Press release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
